


### AMENDMENTS TO THE CLAIMS

Claims 1-14 (canceled)

Claim 15 (currently amended): A composition of matter comprising a  
5 carrier and a tumor inhibiting effective amount of a compound selected from the  
group consisting of 5-androstene-3 $\beta$ ,17 $\alpha$ -diol and an ester or ether thereof of the  
formula: ~~A composition for inhibiting tumors comprising a tumor inhibiting~~  
~~effective amount of 5-androstene-3 $\beta$ ,17 $\alpha$ -diol or an ester or ether thereof of the~~  
formula:



wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of  
1-4 carbons, phenyl or COR<sub>2</sub>, wherein R<sub>2</sub> is H; alkyl of 1-8 carbons, alkenyl of 2-8  
carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or  
15 phenyl, and any phenyl moiety may have up to three substituents chosen from  
among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4  
carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain,  
branched chain, or the alkyl may be wholly or partially cyclized, wherein said  
composition is in a form appropriate for oral, parenteral, buccal, sublingual,  
20 nasal, endotracheal, rectal, vaginal, cervical, or aerosol administration.

wherein,

R independently are H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR<sub>2</sub>,


R<sub>2</sub> independently are H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons or phenyl, wherein any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, wherein the composition is a formulation for oral, parenteral, buccal, sublingual, endotracheal or aerosol administration.

Claim 16 (currently amended): The composition of claim 15 wherein the compound is ~~composition contains~~ 5-androstene-3 $\beta$ ,17 $\alpha$ -diol.

Claim 17 (previously amended): The composition of claim 15 in the form of a tablet.

Claim 18 (previously amended): The composition of claim 15 in the form of a capsule.

Claim 19 (currently amended): A composition of matter comprising a cyclodextrin and a tumor inhibiting effective amount of a compound selected from the group consisting of 5-androstene-3 $\beta$ ,17 $\alpha$ -diol and an ester or ether thereof of the formula: ~~A composition for inhibiting tumors comprising a tumor inhibiting effective amount of 5-androstene-3 $\beta$ ,17 $\alpha$ -diol or an ester or ether thereof of the formula:~~



wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR<sub>2</sub>, wherein R<sub>2</sub> is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, wherein said composition 5-androstene-3β,17α-diol or an ester or other thereof is part of a cyclodextrin inclusion complex.

wherein,

R are selected from H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR<sub>2</sub>,

R<sub>2</sub> are selected from H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons or phenyl, wherein any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, wherein said composition is a

formulation for oral, parenteral, buccal, sublingual, endotracheal or aerosol administration.

5        Claim 20 (currently amended): The composition of claim 19 wherein the compound is ~~composition contains~~ 5-androstene-3 $\beta$ ,17 $\alpha$ -diol.

Claim 21 (canceled)

10        Claim 22 (currently amended): The composition of claim 19 in the form of a tablet or a capsule.

Claim 23 (currently amended): The composition of claim 19 in the form of a parenteral formulation. [capsule.]

15        Claim 24 (previously added): The composition of claim 19, wherein said composition is in a form selected from the group consisting of a spray, a cream, a jelly, a suppository, a douching solution, a liquid and an adhesive patch.